Yusheng Han Buys 104,650 Shares of Burning Rock Biotech (NASDAQ:BNR) Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han bought 104,650 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was bought at an average price of $7.45 per share, for a total transaction of $779,642.50. Following the acquisition, the director directly owned 18,123,196 shares of the company’s stock, valued at approximately $135,017,810.20. This represents a 0.58% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $8.00 per share, with a total value of $199,200.00.
• On Wednesday, June 24th, Yusheng Han bought 250,000 shares of Burning Rock Biotech stock. The shares were purchased at an average cost of $8.00 per share, for a total transaction of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han purchased 5,990 shares of Burning Rock Biotech stock. The shares were acquired at an average price of $7.50 per share, for a total transaction of $44,925.00.
• On Tuesday, June 16th, Yusheng Han purchased 111,110 shares of Burning Rock Biotech stock. The shares were acquired at an average price of $9.00 per share, for a total transaction of $999,990.00.
• On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $9.25 per share, with a total value of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han acquired 24,760 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $8.74 per share, with a total value of $216,402.40.

Burning Rock Biotech Trading Up 7.0%

Shares of Burning Rock Biotech stock opened at $8.96 on Thursday. The firm has a market cap of $94.26 million, a PE ratio of -10.93 and a beta of 1.33. Burning Rock Biotech Limited Sponsored ADR has a 1 year low of $3.22 and a 1 year high of $41.72. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.05 and a quick ratio of 2.81. The stock has a fifty day moving average price of $12.79 and a 200-day moving average price of $20.08.

Burning Rock Biotech (NASDAQ:BNR) last issued its quarterly earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.29) by $2.09. The company had revenue of $15.66 million for the quarter, compared to the consensus estimate of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Institutional Trading of Burning Rock Biotech

A number of hedge funds and other institutional investors have recently made changes to their positions in BNR. Crcm LP raised its stake in shares of Burning Rock Biotech by 13.8% during the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after purchasing an additional 26,809 shares during the period. Prospera Financial Services Inc boosted its stake in Burning Rock Biotech by 26.0% in the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after purchasing an additional 6,430 shares during the period. Marshall Wace LLP bought a new position in Burning Rock Biotech in the 4th quarter worth about $220,000. Finally, Renaissance Technologies LLC grew its holdings in Burning Rock Biotech by 13.8% during the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after buying an additional 4,290 shares in the last quarter. 30.03% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on BNR. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. Wall Street Zen downgraded Burning Rock Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.